Complete Filing Data
Bicara Therapeutics Inc. reported Stockholders Equity of $401.45 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Bicara Therapeutics Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income Loss | -$138.0M | -$68.0M | -$52.0M |
| Operating Income Loss | -$155.6M | -$82.4M | -$39.9M |
| Operating Expenses | $155.6M | $82.4M | $39.9M |
| Nonoperating Income Expense | $17.9M | $14.6M | -$12.1M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$137.7M | -$67.8M | -$52.0M |
| General And Administrative Expense | $30.5M | $18.8M | $9.3M |
| Research And Development Expense | $63.6M | $30.6M | |
| Income Tax Expense Benefit | $217.0K | $187.0K | |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $243.0K | $0.00 | |
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | $243.0K | $0.00 | |
| Income Taxes Paid | |||
| Comprehensive Income Net Of Tax | -$137.7M | -$68.0M | |
| Tangible Asset Impairment Charges | $0.00 | $568.0K | |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $243.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$36.3M | -$27.4M | -$36.8M | -$17.5M | -$17.0M | -$12.5M | -$22.8M | -$9.3M | -$7.4M |
| Operating Income Loss | -$40.7M | -$32.0M | -$41.8M | -$20.6M | -$19.8M | -$15.4M | -$9.5M | ||
| Operating Expenses | $40.7M | $32.0M | $41.8M | $20.6M | $19.8M | $15.4M | $9.5M | ||
| Nonoperating Income Expense | $4.4M | $4.7M | $5.0M | $3.1M | $2.7M | $2.9M | -$13.3M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$36.3M | -$27.3M | -$36.8M | -$17.5M | -$17.0M | -$12.5M | -$22.8M | ||
| General And Administrative Expense | $7.7M | $7.2M | $7.5M | $4.8M | $3.9M | $3.3M | $2.6M | ||
| Research And Development Expense | $33.0M | $24.8M | $34.3M | $15.9M | $15.8M | $12.0M | $6.9M | ||
| Income Tax Expense Benefit | $40.0K | $52.0K | $72.0K | $0.00 | $0.00 | $1.0K | $0.00 | ||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$136.0K | $0.00 | |||||||
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | -$136.0K | $0.00 | |||||||
| Income Taxes Paid | $72.0K | $1.0K | |||||||
| Comprehensive Income Net Of Tax | -$36.5M | -$17.5M | |||||||
| Tangible Asset Impairment Charges | |||||||||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$136.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $401.5M | $491.9M | -$148.8M | -$98.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $96.7M | $489.7M | $230.4M | $4.2M |
| Retained Earnings Accumulated Deficit | -$359.0M | -$221.0M | -$153.0M | |
| Property Plant And Equipment Net | $330.0K | $155.0K | $202.0K | |
| Prepaid Expense And Other Assets Current | $7.3M | $12.8M | $633.0K | |
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | |
| Other Assets Noncurrent | $6.9M | $6.6M | $2.1M | |
| Operating Lease Right Of Use Asset | $1.7M | $690.0K | $613.0K | |
| Operating Lease Liability Noncurrent | $593.0K | $131.0K | $372.0K | |
| Operating Lease Liability Current | $1.1M | $607.0K | $285.0K | |
| Liabilities Current | $28.9M | $18.0M | $15.1M | |
| Liabilities And Stockholders Equity | $431.0M | $510.0M | $234.0M | |
| Liabilities | $29.5M | $18.1M | $15.5M | |
| Common Stock Value | $7.0K | $7.0K | $2.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$393.0M | $259.3M | $226.3M | |
| Cash And Cash Equivalents At Carrying Value | $96.7M | $489.7M | $230.4M | |
| Assets Current | $422.1M | $502.5M | $231.1M | |
| Assets | $431.0M | $510.0M | $234.0M | |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $1.9M | $413.0K | $703.0K | |
| Operating Lease Right Of Use Asset Amortization Expense | ||||
| Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability | $0.00 | $13.4M | ||
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | $367.3M | ||
| Short Term Investments | $318.1M | $0.00 | ||
| Settlement Of Freestanding Financial Instrument Liabilities | $0.00 | $14.0M | ||
| Other Liabilities Noncurrent | $0.00 | $17.0K | ||
| Operating Lease Right Of Use Asset Periodic Reduction Including Adjustments | $895.0K | -$77.0K | $90.0K | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $243.0K | $0.00 | ||
| Accretion Amortization Of Discounts And Premiums Investments | -$301.0K | $0.00 | ||
| Long Term Investments |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $402.8M | $435.2M | $459.0M | $509.6M | -$174.8M | -$160.1M | -$137.1M | -$114.8M | -$105.9M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $171.7M | $436.6M | $462.1M | $520.8M | $203.9M | $216.0M | $44.2M | |||
| Retained Earnings Accumulated Deficit | -$321.6M | -$285.3M | -$257.9M | -$200.1M | ||||||
| Property Plant And Equipment Net | $135.0K | $117.0K | $136.0K | $130.0K | ||||||
| Prepaid Expense And Other Assets Current | $7.2M | $7.8M | $8.7M | $756.0K | ||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Other Assets Noncurrent | $7.8M | $6.8M | $6.6M | $2.1M | ||||||
| Operating Lease Right Of Use Asset | $2.0M | $2.2M | $552.0K | $414.0K | ||||||
| Operating Lease Liability Noncurrent | $880.0K | $1.2M | $0.00 | $137.0K | ||||||
| Operating Lease Liability Current | $1.1M | $1.1M | $591.0K | $308.0K | ||||||
| Liabilities Current | $21.0M | $17.2M | $19.1M | $14.5M | ||||||
| Liabilities And Stockholders Equity | $424.7M | $453.6M | $478.1M | $524.2M | ||||||
| Liabilities | $21.9M | $18.4M | $19.1M | $14.6M | ||||||
| Common Stock Value | $7.0K | $7.0K | $7.0K | $7.0K | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$27.6M | -$14.4M | ||||||||
| Cash And Cash Equivalents At Carrying Value | $171.7M | $436.6M | $462.1M | $520.8M | ||||||
| Assets Current | $297.4M | $444.4M | $470.8M | $521.5M | ||||||
| Assets | $424.7M | $453.6M | $478.1M | $524.2M | ||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | ||||||||||
| Operating Lease Right Of Use Asset Amortization Expense | $138.0K | $65.0K | ||||||||
| Fair Value Adjustment Of Redeemable Preferred Stock And Freestanding Financial Instrument Liability | $0.00 | $13.3M | ||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | |||||||||
| Short Term Investments | $118.5M | |||||||||
| Settlement Of Freestanding Financial Instrument Liabilities | ||||||||||
| Other Liabilities Noncurrent | $0.00 | |||||||||
| Operating Lease Right Of Use Asset Periodic Reduction Including Adjustments | ||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$136.0K | |||||||||
| Accretion Amortization Of Discounts And Premiums Investments | ||||||||||
| Long Term Investments | $117.4M | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $15.0M | $7.4M | $1.9M |
| Proceeds From Stock Options Exercised | $2.8M | $1.6M | $149.0K |
| Proceeds From Sale Of Property Plant And Equipment | $0.00 | $62.0K | $0.00 |
| Payments To Acquire Property Plant And Equipment | $280.0K | $71.0K | $586.0K |
| Net Cash Provided By Used In Operating Activities | -$106.8M | -$74.8M | -$45.6M |
| Net Cash Provided By Used In Investing Activities | -$318.5M | -$9.0K | -$586.0K |
| Net Cash Provided By Used In Financing Activities | $32.3M | $334.0M | $272.5M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$5.3M | $16.9M | $914.0K |
| Increase Decrease In Operating Lease Liability | -$932.0K | $81.0K | -$47.0K |
| Proceeds From Issuance Of Common Stock | $29.5M | $332.4M | $0.00 |
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability | $0.00 | $272.3M | |
| Payments To Acquire Investments | $318.2M | $0.00 | |
| Payments Of Stock Issuance Costs |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q3 2024 | Q1 2024 |
|---|---|---|---|
| Share Based Compensation | $3.5M | $1.1M | |
| Proceeds From Stock Options Exercised | $460.0K | $137.0K | |
| Proceeds From Sale Of Property Plant And Equipment | $0.00 | $62.0K | |
| Payments To Acquire Property Plant And Equipment | $0.00 | $4.0K | |
| Net Cash Provided By Used In Operating Activities | -$28.1M | -$14.6M | |
| Net Cash Provided By Used In Investing Activities | $0.00 | $58.0K | |
| Net Cash Provided By Used In Financing Activities | $460.0K | $137.0K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$4.1M | $235.0K | |
| Increase Decrease In Operating Lease Liability | -$147.0K | -$68.0K | |
| Proceeds From Issuance Of Common Stock | |||
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Freestanding Financial Instrument Liability | |||
| Payments To Acquire Investments | |||
| Payments Of Stock Issuance Costs | $29.8M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 54.68B | 16.81B | 580.1M | |
| Weighted Average Number Of Diluted Shares Outstanding | 54.68B | 16.81B | 580.1M | |
| Earnings Per Share Diluted | $-2.52 | $-4.05 | $-89.61 | |
| Earnings Per Share Basic | $-2.52 | $-4.05 | $-89.61 | |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Authorized | 500.0M | 500.0M | 365.0M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | |
| Common Stock Shares Outstanding | 56.6M | 54.4M | 640.4K | |
| Common Stock Shares Issued | 56.6M | 54.4M | 711.9K | |
| Temporary Equity Par Or Stated Value Per Share | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 54.6M | 54.5M | 54.5M | 10.9M | 896.7K | 660.3K | 597.6K |
| Weighted Average Number Of Diluted Shares Outstanding | 54.6M | 54.5M | 54.5M | 10.9M | 896.7K | 660.3K | 597.6K |
| Earnings Per Share Diluted | $-0.67 | $-0.50 | $-0.68 | $-1.60 | $-19.01 | $-18.94 | $-38.23 |
| Earnings Per Share Basic | $-0.67 | $-0.50 | $-0.68 | $-1.60 | $-19.01 | $-18.94 | $-38.23 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Common Stock Shares Outstanding | 54.6M | 54.6M | 54.5M | 54.4M | |||
| Common Stock Shares Issued | 54.6M | 54.6M | 54.5M | 54.4M | |||
| Temporary Equity Par Or Stated Value Per Share |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $2.8M | $1.7M | $120.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $15.0M | $7.4M | $1.9M |
| Investment Income Interest | $17.9M | $14.6M | $1.3M |
| Depreciation | $105.0K | $56.0K | $19.0K |
| Additional Paid In Capital | $760.2M | $712.9M | $4.3M |
| Vesting Of Early Exercise Stock Options | $68.0K | $68.0K | |
| Stock Issued During Period Shares Stock Options Exercised | 556.7K | 416.6K | |
| Stock Issued During Period Value New Issues | $29.5M | $332.4M | |
| Stock Issued During Period Value Conversion Of Convertible Securities | $367.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $436.0K | $135.0K | $477.0K | $199.0K | $1.3M | $50.0K | $32.0K | $27.0K | $43.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $3.6M | $3.5M | $3.5M | $2.0M | $1.0M | $1.1M | $519.0K | $352.0K | $264.0K |
| Investment Income Interest | $4.4M | $4.7M | $5.0M | $3.1M | $2.7M | $2.9M | $13.0K | ||
| Depreciation | $19.0K | $13.0K | |||||||
| Additional Paid In Capital | $724.5M | $720.4M | $716.8M | $709.6M | |||||
| Vesting Of Early Exercise Stock Options | $17.0K | $17.0K | |||||||
| Stock Issued During Period Shares Stock Options Exercised | 89.0K | ||||||||
| Stock Issued During Period Value New Issues | $332.4M | ||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $367.2M |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.